<DOC>
	<DOCNO>NCT00580359</DOCNO>
	<brief_summary>This study open-label , single-center , randomized phase II study design evaluate efficacy safety S-1 capecitabine elderly and/or poor performance status patient recurrent metastatic gastric cancer . The randomization stratify age ( 70-85 year versus 65 year &lt; 70 year ) performance status , dependent age group ; 70-85 year , ECOG performance status 0-1 versus 2 ³65 year &lt; 70 year , ECOG performance status 2 versus 3 . - S-1 40mg/m2 orally twice daily day 1 ( even ) - 15 ( morning ) - Capecitabine 1250mg/m2 orally twice daily day 1 ( even ) - 15 ( morning ) Treatment administer every 3 week continue absence disease progression unacceptable toxicity .</brief_summary>
	<brief_title>S-1 v Capecitabine Elderly and/or Poor Performance Status Patients With Recurrent Metastatic Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>1 . Histologically cytologically confirm gastric adenocarcinoma recurrent metastatic disease 2 . Age 7085 year Eastern Cooperative Oncology Group ( ECOG ) performance status 02 age ≥65 &lt; 70 ECOG performance status ≥ 2 3 . Measurable disease define Response Evaluation Criteria In Solid Tumors ( RECIST ) Measurable lesion : Lesions accurately measure least one dimension following : Computed tomography ( CT ) abdomen , pelvis thorax , long diameter record least 10 mm spiral CT Chest xray , lung lesion record clearly define surround aerated lung diameter record least 20 mm Physical examination , clinically detect lesion superficial ( e.g. , skin nodule palpable lymph node ) least 10 mm 4 . No prior chemotherapy recurrent and/or metastatic disease ( prior adjuvant/neoadjuvant chemotherapy allow least 6 month relapse completion adjuvant/neoadjuvant therapy enrolment therapy ; prior S1 capecitabine allow ) 5 . Adequate major organ function include follow : Hematopoietic function : absolute neutrophil count ( ANC ) ≥1,500/mm3 , Platelet ≥ 100,000/mm3 , Hepatic function : serum bilirubin = &lt; 1.5 x upper limit normal ( ULN ) , AST/ALT level = &lt; 2.5 x ULN ( 5 x ULN liver metastasis present ) Renal function : serum creatinine = &lt; 1.5 x ULN 6 . Patients sign write informed consent study entry 1 . Lack physical integrity upper gastrointestinal tract malabsorption syndrome ( e.g . patient partial total gastrectomy enter study , jejunostomy probe ) , inability take oral medication 2 . Patients active ( significant uncontrolled ) gastrointestinal bleed 3 . Inadequate cardiovascular function : New York Heart Association class III IV heart disease Unstable angina myocardial infarction within past 6 month History significant ventricular arrhythmia require medication antiarrhythmic significant conduction system abnormality 4 . Serious concurrent infection nonmalignant illness uncontrolled whose control may jeopardize complication study therapy 5 . Other malignancy within past 3 year except nonmelanomatous skin cancer carcinoma situ cervix 6 . History current brain metastasis 7 . Psychiatric disorder would preclude compliance 8 . Known dihydropyrimidine dehydrogenase deficiency 9 . Patients receive concomitant treatment drug interact S1 capecitabine flucytosine , phenytoin , warfarin , lamivudine , allopurinol et al . 10 . Patients know active infection HIV , HBV , HCV 11 . Major surgery within 4 week start study treatment , without complete recovery 12 . Radiotherapy within 4 week start study treatment ; 2 week interval allow palliative radiotherapy give bone metastatic site patient recover acute toxicity</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Stomach Neoplasms</keyword>
	<keyword>Secondary</keyword>
	<keyword>Combination chemotherapy</keyword>
	<keyword>S-1</keyword>
	<keyword>Capecitabine</keyword>
</DOC>